Hematologic Oncology

Tambiciclib plus azacitidine and venetoclax generated favorable ORR, OS, and safety outcomes in patients with relapsed/refractory acute myeloid leukemia.

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

Stefano Luminari, MD, discusses unmet needs for patients with follicular lymphoma, updated data from the ELM-2 trial, and infection risk management advice.

Certain factors were associated with sustained remission with obe-cel in acute lymphoblastic leukemia.

Hetty E. Carraway, MD, MBA, discusses shifting treatment paradigms in AML from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

The FDA received a BLA resubmission for tabelecleucel in EBV-positive post-transplant lymphoproliferative disease.

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.

Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.

Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

Bexobrutideg received European Medicines Agency orphan drug designation for Waldenström macroglobulinemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss quality-of-life data for obe-cel in acute lymphoblastic leukemia.

Bijal Shah, MD, MS, and Jae Park, MD, discuss other key data in acute lymphoblastic leukemia from EHA 2025.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the implications of the FDA approval of Iptacopan for PNH.

Bezuclastinib improved total symptom score vs placebo in non-advanced systemic mastocytosis, meeting the primary end point of the SUMMIT trial.

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, on the current management of paroxysmal nocturnal hemoglobinuria.

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of NXC-201 in relapsed/refractory light chain amyloidosis.

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.